Recognized as one of the best Realtors in Estero, FL, Jesse McGreevy combines #1 Southwest Florida team leadership, $860M+ in career sales, and decades of luxury-market performance in one of the region's most competitive resort-style markets.
Read More
Peyton McDaniel, guard for Sun Belt Conference women's basketball champion James Madison University, says the sam® sustained acoustic medicine device helps her stay healthy, recover faster, and play at her peak throughout the long season.
Read More
Latest advancement in LeadStar's evolution reinforces AmeriLife's foundational commitment to building enduring agent-client relationships through personalized, face-to-face Medicare consultations
Read More
AI Nose drove 499% revenue growth in 2025, with gross margin turning positive to 82.9%
2025 partnerships now driving scaled AI Nose deployments in 2026, supported by disciplined financing
Read More
The launch of "Golf's New Voice" by GOLF.AIStudios will be a landmark moment for the sport and the rapidly evolving world of artificial intelligence as it's the first time one of golf's all-time greats will combine his global experience, expertise and nuanced knowledge of golf with the power of AI to deliver an unsurpassed viewing experience for over 150 million golfers worldwide. And GOLF.AI is honored to have partnered with Sir Nick Faldo to take this concept and transform it into reality.
Read MoreAn Unparalleled Entry Point Into the Future of Electric Mobility - Where Visionary Capital Meets Transformational Speed
Elektros Inc. Unleashes a Breakthrough That Could Redefine the Economics of Electric Mobility
Read More
Planning for retirement in April 2026 continues to require a strategic approach as inflation concerns, economic uncertainty, and market volatility remain key factors affecting long-term portfolios. As a result, Gold IRAs have continued gaining traction among investors looking for stability and diversification.
Read More
The show also broadcasts across MENA and Latin America as sponsored programming.
Read MoreOne-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once daily pill for moderate-to-severe plaque psoriasis
Results further support the differentiated profile of ICOTYDE, the first and only IL-23 receptor targeted oral peptide
Read More